TY - JOUR T1 - Early clinical markers of aggressive multiple sclerosis JF - medRxiv DO - 10.1101/19002063 SP - 19002063 AU - Charles B Malpas AU - Ali Manouchehrinia AU - Sifat Sharmin AU - Izanne Roos AU - Dana Horakova AU - Eva Kubala Havrdova AU - Maria Trojano AU - Guillermo Izquierdo AU - Sara Eichau AU - Roberto Bergamaschi AU - Patrizia Sola AU - Diana Ferraro AU - Alessandra Lugaresi AU - Alexandre Prat AU - Marc Girard AU - Pierre Duquette AU - Pierre Grammond AU - Francois Grand’Maison AU - Serkan Ozakbas AU - Vincent Van Pesch AU - Franco Granella AU - Raymond Hupperts AU - Eugenio Pucci AU - Cavit Boz AU - Gerardo Iuliano AU - Youssef Sidhom AU - Riadh Gouider AU - Daniele Spitaleri AU - Helmut Butzkueven AU - Aysun Soysal AU - Thor Petersen AU - Freek Verheul AU - Rana Karabudak AU - Recai Turkoglu AU - Cristina Ramo-Tello AU - Murat Terzi AU - Edgardo Cristiano AU - Mark Slee AU - Pamela McCombe AU - Richard Macdonell AU - Yara Fragoso AU - Javier Olascoaga AU - Ayse Altintas AU - Tomas Olsson AU - Jan Hillert AU - Tomas Kalincik AU - on behalf of the MSBase Study Group Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/07/16/19002063.abstract N2 - Patients with the ‘aggressive’ form of MS accrue disability at an accelerated rate, typically reaching EDSS >= 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive MS, but less research has focused on clinical markers that are present in the first year of disease. The development of early predictive models of aggressive MS is essential to optimise treatment in this MS subtype. We evaluated whether patients who will develop aggressive MS can be identified based on early clinical markers, and to replicate this analysis in an independent cohort. Patient data were obtained from MSBase. Inclusion criteria were (a) first recorded disability score (EDSS) within 12 months of symptom onset, (b) at least 2 recorded EDSS scores, and (c) at least 10 years of observation time. Patients were classified as having ‘aggressive MS’ if they: (a) reached EDSS >= 6 within 10 years of symptom onset, (b) EDSS >=6 was confirmed and sustained over >=6 months, and (c) EDSS >=6 was sustained until the end of follow-up. Clinical predictors included patient variables (sex, age at onset, baseline EDSS, disease duration at first visit) and recorded relapses in the first 12 months since disease onset (count, pyramidal signs, bowel-bladder symptoms, cerebellar signs, incomplete relapse recovery, steroid administration, hospitalisation). Predictors were evaluated using Bayesian Model Averaging (BMA). Independent validation was performed using data from the Swedish MS Registry. Of the 2,403 patients identified, 145 were classified as having aggressive MS (6%). BMA identified three statistical predictors: age > 35 at symptom onset, EDSS >= 3 in the first year, and the presence of pyramidal signs in the first year. This model significantly predicted aggressive MS (AUC = .80, 95% CIs = .75, .84). The presence of all three signs was strongly predictive, with 32% of such patients meeting aggressive disease criteria. The absence of all three signs was associated with a 1.4% risk. Of the 556 eligible patients in the Swedish MS Registry cohort, 34 (6%) met criteria for aggressive MS. The combination of all three signs was also predictive in this cohort (AUC = .75, 95% CIs = .66, .84). Taken together, these findings suggest that older age at symptom onset, greater disability during the first year, and pyramidal signs in the first year are early indicators of aggressive MS.Competing Interest StatementCharles Malpas: nothing to disclose. Ali Manouchehrinia is supported by Margaretha af Ugglas foundation. He has received consultancy fees from Biogen and speaker honoraria and/or travel expenses from Biogen and ECTRIMS. Sifat Sharmin: nothing to disclose Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague [PRVOUK-P26/LF1/4], Czech Minsitry of Education [PROGRES Q27/LF1] and Czech Ministry of Health [NT13237-4/2012]. Eva Kubala Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva, and support for research activities from Czech Ministry of Education [project Progres Q27/LF1]. Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis. Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva. Sara Eichau received speaker honoraria and consultant fees from Biogen, Merck, Novartis, Almirall, Roche, Sanofi and Teva. Roberto Bergamaschi received speaker honoraria from Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva; research grants from Bayer Schering, Biogen, Merck, Novartis, Sanofi-Aventis, Teva; congress and travel/accommodation expense compensations by Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva. Patrizia Sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva. Diana Ferraro received travel grants and/or speaker honoraria from Merck, TEVA,?Novartis, Biogen and Sanofi-Genzyme. Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Roche, Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Alexandre Prat did not declare any competing interests. Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD.? He has also received a research grant from Canadian Institutes of Health Research. Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme. Pierre Grammond is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis. Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals. Serkan Ozakbas did not declare any competing interests. Vincent Van Pesch received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering. Franco Granella received research grant from Biogen, served on scientific advisory boards for Biogen, Novartis, Merck, and Sanofi-Aventis and received funding for travel and speaker honoraria from Biogen, Merck, Sanofi-Aventis, and Almirall. Raymond Hupperts received honoraria as consultant on scientific advisory boards from Merck, Biogen, Genzyme-Sanofi and Teva, research funding from Merck and Biogen, and speaker honoraria from Sanofi-Genzyme and Novartis. Eugenio Pucci served on scientific advisory boards for Merck, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche". Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen. Cavit Boz received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis. Gerardo Iuliano had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck, Novartis, Sanofi Aventis, and Teva. Youssef Sidhom did not declare any competing interests. Riadh Gouider did not declare any competing interests. Daniele Spitaleri received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva and Merck. Helmut Butzkueven served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen and Novartis, and has received research support from Merck, Novartis and Biogen. Aysun Soysal did not declare any competing interests. Thor Petersen received funding or speaker honoraria from Biogen, Merck, Novartis, Bayer Schering, Sanofi-Aventis, Roche, and Genzyme. Freek Verheul is an advisory board member for Teva Biogen Merck and Novartis. Rana Karabudak did not declare any competing interests. Recai Turkoglu did not declare any competing interests. Cristina Ramo-Tello received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall. Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis. Edgardo Cristiano received honoraria as consultant on scientific advisory boards by Biogen, Bayer-Schering, Merck, Genzyme and Novartis; has participated in clinical trials/other research projects by Merck, Roche and Novartis. Mark Slee has participated in, but not received honoraria for, advisory board activity for Biogen, Merck, Bayer Schering, Sanofi Aventis and Novartis. Pamela McCombe did not declare any competing interests. Richard Macdonell did not declare any competing interests. Yara Fragoso received honoraria as a consultant on scientific advisory boards by Novartis, Teva, Roche and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva, Roche and Merck. Javier Olascoaga serves on scientific advisory boards for Biogen, Novartis, Sanofi and Roche; has received speaker honoraria from Almirall, Biogen, Bayer, Sanofi, Merck, Novartis and Roche and research grants from Biogen, Merck, Novartis and Teva. Ayse Altintas received personal fees and speaker honoraria from Teva, Merck, Novartis, Sanofi-Genzyme; received travel and registration grants from Merck, Roche, Sanofi-Genzyme. Tomas Olsson has received honoraria for lectures/advisory boards and/or unrestricted MS research grants from Biogen, Novartis, Sanofi, Merck and Roche Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.Funding StatementThis study was financially supported by the National Health and Medical Research Council of Australia (1129189, 1140766, 1080518). The MSBase Foundation is a not-for-profit organisation that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme and Teva. The study was conducted separately and apart from the guidance of the sponsors.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData were obtained from the international MSBase cohort study. Information regarding data availability can be obtained at https://www.msbase.org/. https://www.msbase.org/ ER -